ReviewInternational journal of nephrology and renovascular disease2018
Peritoneal dialysis-related peritonitis: challenges and solutions.
Review in International journal of nephrology and renovascular disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- A systematic review of the cost-effectiveness of renal replacement therapies, and consequences for decision-making in the end-stage renal disease treatment pathway.The European journal of health economics : HEPAC : health economics in prevention and care · 2023Pooled it
- Moraxella peritoneal dialysis-related infections: a systematic review.Jornal brasileiro de nefrologiaPooled it
- Comparative effectiveness of lactulose and sennosides for the prevention of peritoneal dialysis-related peritonitis: an open-label, randomized, active-controlled trial.Annals of medicine · 2021Trial
- Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2021Trial
- Roxadustat and incidence of peritoneal dialysis-associated peritonitis: a propensity score-matched cohort study.Clinical and experimental nephrology · 2026Article
- Peritonitis and Mortality Risks of Gastric Acid Suppressants in Patients Undergoing Peritoneal Dialysis.Kidney international reports · 2026Article
- Article
- Association between serum potassium levels and peritonitis in peritoneal dialysis patients: a longitudinal study.BMC nephrology · 2026Observational
- A Case of Peritoneal Dialysis-Associated Peritonitis Due toCase reports in infectious diseases · 2026Article
- Article
- Effectiveness and safety of thymopentin for infection prophylaxis in peritoneal dialysis patients: a retrospective study.BMC nephrology · 2025Article
- Factors influencing the symptom-to-contact time in patients with peritoneal dialysis-associated peritonitis: a multi-center retrospective study.BMC nephrology · 2025Article
- Flying under the radar: vancomycin heteroresistance inASM case reports · 2025Article
- Cost Analysis of Hospital Treatment for Peritoneal Dialysis-Associated Peritonitis.Iranian journal of public health · 2025Article
- Review
- Prevalence, microbiology, and outcome of peritonitis in peritoneal dialysis patients in vietnam: a multicenter study.BMC nephrology · 2025Article
- Case Report: Peritoneal dialysis-associated peritonitis caused byFrontiers in medicine · 2025Article
- Epidemiology, drug resistance, and clinical risk factors of peritoneal dialysis-associated peritonitis: a five-year multicenter study.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peritoneal dialysis is an effective treatment modality for patients with end-stage renal disease. The relative use of peritoneal dialysis versus hemodialysis varies widely by country. Data from a 2004 survey reports the percentage of patients with end-stage renal disease treated with peritoneal dialysis to be 5%-10% in economically developed regions like the US and Western Europe to as much as 75% in Mexico. This disparity is probably related to the availability and access to hemodialysis, or in some cases patient preference for peritoneal over hemodialysis. Peritoneal dialysis-related peritonitis remains the major complication and primary challenge to the long-term success of peritoneal dialysis. Fifty years ago, with the advent of the Tenckhoff catheter, patients averaged six episodes of peritonitis per year on peritoneal dialysis. In 2016, the International Society for Peritoneal Dialysis proposed a benchmark of 0.5 episodes of peritonitis per year or one episode every 2 years. Despite the marked reduction in peritonitis over time, peritonitis for the individual patient is problematic. The mortality for an episode of peritonitis is 5% and is a cofactor for mortality in another 16% of affected patients. Prevention of peritonitis and prompt and appropriate management of peritonitis is essential for the long-term success of peritoneal dialysis in all patients. In this review, challenges and solutions are addressed regarding the pathogenesis, clinical features, diagnosis, treatment, and prevention of peritoneal dialysis-related peritonitis from the viewpoint of an infectious disease physician.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.